Combined treatment with MEK and mTOR inhibitors is effective in vitro and in vivo models of hepatocellular carcinoma

URN to cite this document:: urn:nbn:de:bvb:355-epub-415808
DOI to cite this document:: 10.5283/epub.41580

Liu, Xianqiong ; Hu, Junjie ; Song, Xinhua ; Utpatel, Kirsten ; Evert, Matthias ; Calvisi, Diego F.

Preview

License: Creative Commons Attribution 4.0
PDF - Published Version
(7MB)

Date of publication of this fulltext: 13 Feb 2020 10:35

Alternative links to fulltext:DOI Publisher

Details

Preview

Indexed in

Export bibliographical data

Abstract

Background: Hepatocellular carcinoma (HCC) is the most common primary liver cancer histotype, characterized by high biological aggressiveness and scarce treatment options. Recently, we have established a clinically relevant murine HCC model by co-expressing activated forms of v-akt murine thymoma viral oncogene homolog (AKT) and oncogene c-mesenchymal-epithelial transition (c-Met) proto-oncogenes ...